Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel
Abstract
Authors
J Gaultney A Baka A Leliveld-Kors W Noordzij D Wyndaele C De Meyer